more than 90% of PBC patients but less than 1% of normal controls (Table 1 . In PBC, PDC-E2 is the primary autoantigen to which more than 90% of the antibodies in the patient's serum react [7] . In addition, approximately 50-80% of PBC patients have serum that reacts to BCOADC-E2, 20-60% react to OGDC-E2, 5-25% react to E1α, and 10% react to E3 binding protein (Table 1) 
3: Anti-centromere antibodies (ACAs)
Kinetochore is the protein structure on the centromere, which is composed of more than 100 distinct proteins. It is the site to which spindle fibers attach during cell division to pull sister chromatids apart [9]. ACAs, which were originally found in patients with systemic sclerosis (SSc), are found in a discrete speckled pattern 
4: Other ANAs detected in PBC
Autoantibodies to SUMOs and sp140, which appear in a MND pattern, and autoantibodies to p62 and lamin B receptor, which appear in a NE, are detected in 2-9%, 15%, 10-30%, and 2-9 %, respectively, of PBC patients in a disease-specific manner (Table 1) [37,38,39,45,68,69]. However, the clinical significance of these autoantibodies remains to be determined in patients of different ethnicities.
IV. Three types of PBC progression
Three major forms of PBC were identified by Poupon et al 
V. Conclusion
It is of note that the autoimmune repertoire as represented by autoantibody status, which is established during the early stages of the disease process, Anti-gp210 antibody positivity is a risk factor for hepatic failure-type progression, while anti-centromere antibody positivity is a risk factor for portal hypertension-type progression in Japanese cohort studies [10,11,41,48,49].
